HHV6 Reactivation is an Important Riskfactor for Poor Outcomes in Myeloablative, But Not in Non-Myeloablative Treated Allogeneic HSCT Patients

• 作者A.P.J. Pagter; E. Meijer; L. Keukens; M. Schutten; J.J. Cornelissen; D. Baarle; E. Fries; R. Schuurman; J.J. Boelens
• 卷第15卷
• 印刷ISSN1083-8791
• 文件大小59.24KB
• 发表时间2009
• DOI10.1016/j.bbmt.2008.12.025